| OA02.04 | HIV prevalence and incidence among FSWs participanting in a HIV vaccine preparedness study in Dar es Salaam,Tanzania | Oral Abstract Session | Epidemiology of HIV |
| OA02.05LB | Risk factors for HIV transmission in heterosexual men, men who have sex with men, and transgender women participating in the HVTN 702 'Uhambo' and HVTN 503/503-S 'Phambili' HIV vaccine trials | Oral Abstract Session | Transmission of HIV |
| OA03.01 | Safety and single-dose pharmacokinetics of VRC07-523LS administered via different routes and doses | Oral Abstract Session | Clinical trial results |
| OA03.02 | Safety and PK of Potent Anti-HIV Monoclonal AB VRC07-523LS in HIV-exposed Infants | Oral Abstract Session | Broadly neutralizing antibodies |
| OA03.03 | Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081) | Oral Abstract Session | Broadly neutralizing antibodies |
| OA03.04LB | Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085) | Oral Abstract Session | Broadly neutralizing antibodies |
| OA03.05LB | HIV-1 bnAb M4008_N1 targets a novel site of vulnerability at the V3 crown | Oral Abstract Session | Broadly neutralizing antibodies |
| OA04.01 | User assessment of a microarray patch for HIV PrEP and as a multipurpose prevention technology for HIV and pregnancy prevention: perspectives from Uganda and South Africa | Oral Abstract Session | Behavioural and social science research |
| OA04.02 | High protection against vaginal SHIV infection in macaques by a biodegradable implant releasing tenofovir alafenamide | Oral Abstract Session | Preclinical studies for HIV prevention |
| OA04.03 | Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participants | Oral Abstract Session | Pharmacology/PK and PD studies |